

Clinical Criteria updates

Please note, this communication applies to Anthem HealthKeepers Plus Medicaid products offered by HealthKeepers, Inc.

Summary: On September 12, 2022, and November 18, 2022 the Pharmacy and Therapeutic (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for HealthKeepers, Inc. These policies were developed, revised or reviewed to support clinical coding edits.

Visit [Clinical Criteria](#) to search for specific policies. For questions or additional information, use this [email](#).

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Please note:

- **The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.**
- **This notice is meant to inform the provider of new or revised criteria that has been adopted by HealthKeepers, Inc. only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.**

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
April 27, 2023	*CC-0222	Tecvayli (teclistamab-cqyv)	New
April 27, 2023	*CC-0223	Imjudo (tremelimumab-actl)	New
April 27, 2023	*CC-0224	Pedmark (sodium thiosulfate injection)	New
April 27, 2023	*CC-0225	Tzield (teplizumab)	New
April 27, 2023	CC-0130	Imfinzi (durvalumab)	Revised
April 27, 2023	*CC-0107	Bevacizumab for Non-Ophthalmologic Indications	Revised
April 27, 2023	*CC-0124	Keytruda (pembrolizumab)	Revised
April 27, 2023	*CC-0168	Tecartus (brexucabtagene autoleucel)	Revised
April 27, 2023	*CC-0195	Abecma (idecabtagene vicleucel)	Revised
April 27, 2023	*CC-0150	Kymriah (tisagenlecleucel)	Revised
April 27, 2023	*CC-0151	Yescarta (axicabtagene ciloleucel)	Revised
April 27, 2023	*CC-0187	Breyanzi (lisocabtagene maraleucel)	Revised

<https://providers.anthem.com/va>

Effective date	Document number	<i>Clinical Criteria</i> title	New or revised
April 27, 2023	*CC-0214	Carvykti (ciltacabtagene autoleucel)	Revised
April 27, 2023	CC-0133	Aliqopa (copanlisib)	Revised
April 27, 2023	*CC-0041	Complement Inhibitors	Revised
April 27, 2023	*CC-0003	Immunoglobulins	Revised
April 27, 2023	CC-0072	Selective Vascular Endothelial Growth Factor (VEGF) Antagonists	Revised
April 27, 2023	*CC-0100	Istodax (romidepsin)	Revised
April 27, 2023	*CC-0204	Tivdak (tisotumab vedotin-tftv)	Revised
April 27, 2023	*CC-0205	Fyarro (sirolimus albumin bound)	Revised
April 27, 2023	*CC-0182	Iron Agents	Revised